ArticleOpen heart2026
Early versus delayed EKOS thrombolysis in intermediate-high risk pulmonary embolism: a retrospective multicentre analysis.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedCorrection:2026
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltrasound-assisted catheter-directed thrombolysis using the EkoSonic Endovascular System (EKOS) is an established treatment for intermediate high-risk pulmonary embolism (IHR-PE). However, the optimal timing of treatment initiation remains uncertain. Early right ventricular (RV) unloading may improve outcomes by reducing RV pressure overload and preventing haemodynamic deterioration.
methodsWe conducted a retrospective multicentre analysis of patients with IHR-PE treated with EKOS at three tertiary centres. Patients were stratified by time from CT-confirmed diagnosis to EKOS initiation: early (<12 hours) versus delayed (>12 hours). Echocardiographic parameters included RV/left ventricular (LV) ratio, tricuspid annular plane systolic excursion (TAPSE), LV ejection fraction (LVEF) and systolic pulmonary artery pressure (sPAP). Secondary outcomes were intensive care unit (ICU) length of stay, complications, bleeding events and in-hospital mortality. 3-month follow-up was available in two centres.
resultsOverall, 152 patients were included (early n=106; delayed n=46) in the study. Baseline characteristics were largely comparable, although dyspnoea New York Heart Association (NYHA) class II-III was more frequent in the early group (NYHA III: 73% vs 46%, p=0.001). Both groups showed significant improvements in RV/LV ratio, TAPSE, sPAP and LVEF (all p<0.001). Early treatment resulted in numerically greater RV functional improvement (Early Δ Discharge (D)-Admission (A) TAPSE early 4.86±5.14 mm vs delayed Δ D-A 3.5±5 mm), without statistically significant differences between groups. At 3-month follow-up, RV recovery measured by TAPSE was comparable. Early EKOS therapy was associated with a significantly shorter ICU stay (median 24 hours vs 45.5 hours, p=0.033), fewer PE-related complications (p=0.03), while procedure-related complications and in-hospital mortality did not differ.
conclusionsIn IHR-PE, EKOS initiation within 12 hours is associated with a significantly shorter ICU stay and significantly less PE-related complications. These findings support early EKOS treatment strategies and warrant confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.